Table 2. Associations between urine TMPRSS2:ERG score and clinicopathological parameters among informative academic biopsy (bx) patients (n=606).

The number of patients with data for each parameter is given. (Top) Spearman's rho (r_s) and P value (Spearman rank correlation) for the correlation of each parameter with urine TMPRSS2:ERG score are shown. (Bottom) The median TMPRSS2:ERG score (with 95% confidence interval [CI]) and P values from Wilcoxon Rank-Sum tests are shown.

Parameter		Number of patients (n)	TMPRSS2:ERG score (rs)	P value
Age		606	0.16	< 0.001
PSA		606	0.03	0.45
Ultrasound volume		602	−0.04	0.27
PSAD		602	0.06	0.14
PCPT cancer risk%		463	0.09	0.06
Number of bx cores with cancer1		229	0.18	0.005
Percentage of bx cores with cancer1		229	0.20	0.003
Greatest cancer involvement of a single core (%)1		231	0.24	<0.001
Parameter		Number of patients (n)	Median TMPRSS2:ERG score (95% CI)	P value
Diagnosis
Non-cancer		337	4 (2–6)	<0.001
Cancer		269	40 (30–61)
Diagnosis2
Atypia and/or PIN		89	6 (2–18)	0.02
Other benign		248	3 (1–5)
Race
White		522	12 (8–17)	0.79
Not white		84	8 (5–31)
Family history
Negative		401	11 (6–15)	0.35
Positive		114	12 (5–28)
DRE
Normal		418	11 (7–18)	0.28
Abnormal		171	15 (8–24)
Previous bx3
No		395	15 (9–20)	0.02
Yes		169	5 (2–14)
Number of bx cores
≤12		251	12 (6–24)	0.39
>12		265	8 (5–16)
Gleason score1
6		127	35 (17–57)	0.16
>6		142	49 (30–79)
Clinical stage1
T1		187	47 (33–63)	0.83
>T1		76	35 (17–77)
Bx significance1,4
Insignificant		49	23 (4–38)	0.007
Significant		187	49 (33–77)

¹Only patients with cancerous biopsies (bx).

²Only patients with benign bx.

³Excluding patients on active surveillance.

⁴Epstein criteria: any Bx clinical stage >T1, PSAD≥0.15 ng/ml, Bx Gleason score >6, ≥3 cores positive or greatest cancer involvement of a single core >50% as significant.